Liver Disease News

June 12, 2017June 12, 2017
Eureka, City of Hope to Conduct Phase 1 Trial of Investigational CAR T-cell Therapy for Liver Cancer
Liver cancer, News
Eureka Therapeutics and City of Hope will jointly conduct a Phase 1 clinical trial of assessing Eureka’s investigational CAR T-cell therapy ET1402 for hepatocellular ... Read more
June 9, 2017June 9, 2017
ProSciento and OWL Metabolomics Team Up to Accelerate NAFLD/NASH Trial Recruitment
News
ProSciento and OWL Metabolomics announced an exclusive, long-term partnership to identify eligible participants for clinical trial enrollment to evaluate therapeutic candidates ... Read more
June 8, 2017
Oral Therapy, VK2809, Shows Potential in Treating NASH-related Fibrosis in Early Study
News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis
The investigative therapy VK2809 showed promising results in an animal study of non-alcoholic steatohepatitis (NASH), a type of non-alcoholic fatty ... Read more
June 7, 2017June 7, 2017
SIR-Spheres Radiation Microspheres Outperform Chemo in Liver Cancer Trial
News
SIR-Spheres radiation microspheres shrank the tumors of a significantly larger number of liver cancer patients than the standard-of-care chemotherapy Nexavar (sorafenib), ... Read more
June 6, 2017June 6, 2017
Ocera Starts Second Part of Trial of OCR-002 for Liver Disease That Impacts Mental Functioning
News
Ocera Therapeutics has started the second part of a Phase 1/2a clinical trial of OCR-002 (ornithine phenylacetate) tablets as a ... Read more
June 5, 2017June 5, 2017
Australian Researchers Investigate Zinc as Potential Ally Against Liver Disease
News
A study by Australia’s Westmead Institute has revealed an unexpected role for zinc in liver disease. Researchers at the ... Read more
June 2, 2017June 2, 2017
Digital Support Platform IO Loop Keeps Oncologists and Patients Engaged Throughout Treatment
News
A new digital support platform, IO Loop, is helping patients stay connected online with doctors before, during, and after ... Read more
June 1, 2017June 1, 2017
Drinking More Coffee Can Reduce Risk of Hepatocellular Carcinoma, Scottish Study Finds
News
Coffee consumption can dramatically cut one’ risk of developing hepatocellular carcinoma (HCC), a type of liver cancer, say researchers ... Read more
May 31, 2017May 31, 2017
FDA Grants Priority Review Status to Opdivo Application for Advanced Liver Cancer Patients
Liver cancer, News
The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) submitted by ... Read more
May 30, 2017
Health Canada Approves Ocaliva for Autoimmune Liver Disease Patients
News
Canadian patients with the autoimmune liver disease primary biliary cholangitis (PBC) saw the first approval of a new drug ... Read more
May 26, 2017
SIR-Spheres Radiation Therapy Increases Chance Liver Cancer Can Be Operated on, Study Reports
News
Those with liver cancer that has spread from the colon have a better chance of surgical removal of their ... Read more
May 25, 2017
Change in Intestinal Fungus Mix May Contribute to Alcoholic Liver Disease, Study Reports
Alcoholic liver disease, News
Alcohol alters the intestines’ fungus mix, and the imbalance may contribute to the development and progression of alcoholic liver ... Read more

Liver Cancer

June 12, 2017June 12, 2017
Eureka, City of Hope to Conduct Phase 1 Trial of Investigational CAR T-cell Therapy for Liver Cancer

Eureka Therapeutics and City of Hope will jointly conduct a Phase 1 clinical trial of assessing Eureka’s investigational CAR T-cell therapy ET1402 for hepatocellular carcinoma (HCC), the most common ... Read more
May 31, 2017May 31, 2017
FDA Grants Priority Review Status to Opdivo Application for Advanced Liver Cancer Patients

The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) submitted by Bristol-Myers Squibb seeking approval for ... Read more
May 8, 2017
New ‘Liver Line’ Online Community to Share Updates on Health, Research, Treatments

A new online community, called Liver Line and sponsored by Galectin Therapeutics, offers the latest information on liver health and research into liver diseases. On Liver Line, ... Read more
May 5, 2017May 5, 2017
Can-Fite’s Namodenoson to Enter NAFLD/NASH Phase 2 Clinical Trial

Can-Fite BioPharma has concluded preparations for its Phase 2 trial evaluating namodenoson (CF102) for the treatment of non-alcoholic fatty liver disease (NAFLD). The study will ... Read more

CHRONIC HEPATITIS

May 8, 2017
New ‘Liver Line’ Online Community to Share Updates on Health, Research, Treatments

A new online community, called Liver Line and sponsored by Galectin Therapeutics, offers the latest information on liver health and research into liver diseases. On Liver Line, ... Read more
March 16, 2017April 5, 2017
Coffee Intake May Reduce Risk of Chronic Liver Disease, Study Says

Drinking coffee may reduce the risk of chronic liver disease, especially in patients with other conditions affecting the liver, including non-alcoholic fatty liver disease, ... Read more

Non-alcoholic fatty liver disease

June 8, 2017
Oral Therapy, VK2809, Shows Potential in Treating NASH-related Fibrosis in Early Study

The investigative therapy VK2809 showed promising results in an animal study of non-alcoholic steatohepatitis (NASH), a type of non-alcoholic fatty liver disease, Viking Therapeutics, its developer, announced. ... Read more
May 18, 2017May 18, 2017
Albireo Wins 2 U.S. Patents for A4250 Therapy to Treat NASH, Other Liver Diseases

Albireo Pharma has secured two new patents from the U.S. Patent and Trademark Office (USPTO) for its lead drug candidate A4250 to treat liver diseases such as nonalcoholic steatohepatitis (NASH). ... Read more
May 17, 2017May 17, 2017
Monkey Studies Prove Safety, Tolerability of IVA337 Experimental Therapy for Non-alcoholic Steatohepatitis

Inventiva’s drug candidate IVA337, currently in Phase 2 studies for both non-alcoholic steatohepatitis (NASH) and systemic sclerosis (SSc), has shown a good safety profile in monkeys, ... Read more
May 15, 2017
Early Study to Test Bioelectronic Treatment for NASH Inflammation

A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning, its developer, Endonovo Therapeutics, announced. ... Read more
May 10, 2017May 10, 2017
Novartis Exercises Option to Develop and Market Conatus’ Emricasan to Treat NASH

Novartis is exercising an option to become the exclusive developer and global marketer of Conatus Pharmaceuticals‘ liver-disease treatment emricasan. Under the agreement, signed in December ... Read more
May 9, 2017
First Patient Enrolled in Phase 2 Clinical Trial of Elafibranor for Bile Duct Disease

GENFIT has enrolled the first patient in a Phase 2a clinical trial of elafibranor as a treatment for a liver bile duct disease known as primary biliary ... Read more

Eureka, City of Hope to Conduct Phase 1 Trial of Investigational CAR T-cell Therapy for Liver Cancer

ProSciento and OWL Metabolomics Team Up to Accelerate NAFLD/NASH Trial Recruitment

Oral Therapy, VK2809, Shows Potential in Treating NASH-related Fibrosis in Early Study

SIR-Spheres Radiation Microspheres Outperform Chemo in Liver Cancer Trial

Ocera Starts Second Part of Trial of OCR-002 for Liver Disease That Impacts Mental Functioning

Australian Researchers Investigate Zinc as Potential Ally Against Liver Disease

Digital Support Platform IO Loop Keeps Oncologists and Patients Engaged Throughout Treatment

Drinking More Coffee Can Reduce Risk of Hepatocellular Carcinoma, Scottish Study Finds

FDA Grants Priority Review Status to Opdivo Application for Advanced Liver Cancer Patients

Health Canada Approves Ocaliva for Autoimmune Liver Disease Patients

SIR-Spheres Radiation Therapy Increases Chance Liver Cancer Can Be Operated on, Study Reports

Change in Intestinal Fungus Mix May Contribute to Alcoholic Liver Disease, Study Reports

Non-alcoholic fatty liver disease